Pharmaceuticals, Biotechnology and Life Sciences
Mauna Kea Technologies inventor of Cellvizio, the multidisciplinary confocal laser endomicroscopy platform, announced today the launch of a ground-breaking new clinical study led by researchers at the University of Utah School of Medicine and Harvard Medical School called: “Evaluation of Fiberoptic Confocal Microscopy for Pediatric Cardiac Surgery.”
Bayer has announced that the acquisition facilities of USD 56.9 billion that Bayer had agreed with five underwriter banks (BofA Merrill Lynch, Credit Suisse, Goldman Sachs, HSBC and JP Morgan) prior to announcement of the Monsanto acquisition has now been successfully syndicated within the group of Bayer’s core relationship banks.
Arthritis is very common but is not well understood. Actually, “arthritis” is not a single disease; it is an informal way of referring to joint pain or joint disease.
Hikma Pharmaceuticals has announced that Said Darwazah, Chairman and Chief Executive Officer of Hikma, received the “Leader of the Year Award” at the Global Generics and Biosimilars Awards held in Barcelona on 4 October 2016.
ActuallySheCanSM, the female empowerment campaign by Allergan, has unveiled a striking series of portraits shot by celebrated photographers Inez van…
Ablynx has extended for a second time its research collaboration with a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA, known as MSD outside the United States and Canada, to develop and commercialise Nanobody candidates directed towards an undisclosed voltage gated ion channel.
Although randomised clinical trials (RCTs) remain the gold standard for evaluating the benefit/risk of cancer drugs, single-arm trials (SATs) can provide invaluable opportunities to speed up cancer drug development and approval, in particular for drugs with dramatic activity and strong biological rationale in small populations with high unmet need, Dr. Jorge Martinalbo, Scientific Officer at the European Medicines Agency (EMA) reported at the ESMO 2016 Congress.
BIOPHYTIS, a biotechnology company specialized in the development of drug candidates to treat aging diseases, has announced the implementation of a proprietary e-Health platform, SARA-data, to process patient data from its SARA clinical studies.
The approval of the AC-170 NDA after December 1, 2016 would trigger a milestone payment of $10 million in Nicox shares to ex-Aciex shareholders or $35 million in Nicox shares if approval of the NDA is received before this date.
ABIVAX is hosting an R&D Day at the Company’s new collaborative laboratory with the French National Center for Scientific Research (CNRS) in Montpellier.